Relationship between Patient Demographic Characteristics, Valproic Acid Dosage and Clearance in Adult Iranian Patients

Document Type: Original Article


1 Pharmaceutical Research Centre, Mashhad University of Medical Sciences, Mashhad, Iran

2 Department of Neurology, Faculty of Medicine, Ghaem Hospital, Mashhad University of Medical Sciences, Mashhad, Iran

3 Department of Psychiatry, Faculty of Medicine & Psychiatric Research Centre, Ebn-sina Hospital, Mashad University of Medical Sciences, Mashhad, Iran

4 Department of Medicinal Chemistry, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran

5 Department of Pharmacodinamy & Toxicology, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran


As there are conflicting findings regarding the clearance-dose and patient characteristics relationships for valproic acid (VPA), this study was conducted to investigate the relationship between patient demographic characteristics, VPA dosage and the drug clearance in adult Iranian patients.
Materials and Methods
Patients (N= 47) were either on monotherapy with VPA or were under co-treatment with drugs that have no effect on VPA pharmacokinetic (PK) profile. All of the patients received VPA at therapeutic dose. Steady state trough plasma concentrations of VPA were determined by Fluorescence Polarization Immunoassay (FPIA) and VPA apparent clearance (CL/F) were calculated in each patient.
Mean VPA dose and VPA CL/F were 8.93±2.2 mg/kg/day and 0.65±0.55 l/hr respectively. No significant correlations were found between VPA CL/F and patients' age, TBW and VPA dose. VPA CL/F values of male and female patients were compared and no significant difference between these two groups was noted (P> 0.05). Significant correlation between VPA dose and total trough plasma concentration was found        (P= 0.001). Mean total VPA plasma concentration was 54.51±23.74 mg/l.
Our study showed PK of VPA was not affected by age, sex, TBW and VPA dose. However, for detailed results and construction of VPA PK model in Iranian patients, it is necessary to evaluate VPA PK in a larger sample size with different VPA doses, age and TBW ranges. 


1. Gidal BE, Garnet WR. Epilepsy. In: Dipiro JT, Ta RL, Yee GC, Matzke GR Wells RG, Posey LM. Pharmacotherapy: A Pathophysiologic Approaches. New York: McGraw -Hill; 2005.

2. Evans WE SJ, Jasko Wj. Applied Pharmacokinetics: Principles of Therapeutic Drug Monitoring. Lippincott Williams & Wilkins; 1992.

 3. Vucicevic K, Miljkovic B, Pokrajac  M, Prostran M, Martinovic Z, Grabnar I. The influence of drug-drug interaction and patients' characteristics on valproic acid's clearance in adults with epilepsy using nonlinear mixed effects modeling. Eur J Pharm Sci  2009; 38:512-518.

4. Gidal BE, Pitterle ME, Spencer NW, Maly MM. Relationship between valproic acid dosage, plasma concentration and clearance in adult monotherapy patients with epilepsy. J Clin Pharm Ther  1995; 20:215-219.

5.  Forooghipour  M, Mohammadpour AH, Mashhadian NV, Khayyat MH, Azarpajouh MR, Mokhber N, Aghebati T, et al. Therapeutic drug monitoring of valproic acid in patients with monotherapy at steady state. Iran J Basic Med Sci 2009; 12:146-149.

6.  Fattore C, Messina S, Battino D, Croci D, Mamoli D, Perucca E. The influence of old age and enzyme inducing comedication on the pharmacokinetics of valproic acid at steady-state: A case-matched evaluation based on therapeutic drug monitoring data. Epilepsy Res  2006; 70:153-160.

7. Reith DM, Andrews J, McLaughlin D. Valproic acid has temporal variability in urinary clearance of metabolites. Chronobiol Int  2001; 18:123-129.

8.  Herngren L, Nergardh A. Pharmacokinetics of free and total sodium valproate in adolescents and young adults during maintenance therapy. J  Neurol 1988; 235:491-495.

9.  Battino D, Estienne M, Avanzini G. Clinical pharmacokinetics of antiepileptic drugs in paediatric patients. Part I: Phenobarbital, primidone, valproic acid, ethosuximide and mesuximide. Clin Pharmacokinet  1995; 29:257-286.

10. Bondareva IB, Jelliffe RW, Sokolov AV, Tischenkova  IF. Nonparametric population modeling of valproate pharmacokinetics in epileptic patients using routine serum monitoring data: implications for dosage. J Clin Pharm Ther  2004; 29:105-120.

11. Serrano BB, Garcia Sanchez MJ, Otero MJ, Buelga DS, Serrano J, Dominguez-Gil A. Valproate population pharmacokinetics in children. J Clin Pharm Ther 1999; 24:73-80.

12.  Panomvana Na Ayudhya D, Suwanmanee J, Visudtibhan A. Pharmacokinetic parameters of total and unbound valproic acid and their relationships to seizure control in epileptic children. Am J Ther  2006; 13:211-217.

13. Birnbaum AK, Hardie NA, Conway JM, Bowers SE, Lackner TE, Graves NM , Leppik IE. Valproic acid doses, concentrations, and clearances in elderly nursing home residents. Epilepsy Res  2004; 62:157-162.

14.  Stephen  LJ. Drug treatment of epilepsy in elderly people: focus on valproic Acid. Drugs Aging  2003, 20:141-152.

15.  Jankovic  SM, Milovanovic JR. Pharmacokinetic modeling of valproate from clinical data in Serbian epileptic patients. Methods Find Exp Clin Pharmacol  2007; 29:673-679.

16. Yukawa E, To H, Ohdo S, Higuchi S, Aoyama T. Population-based investigation of valproic acid relative clearance using nonlinear mixed effects modeling: influence of drug-drug interaction and patient characteristics. J Clin Pharmacol  1997; 37:1160-1167.

17. Birnbaum AK, Ahn JE, Brundage RC, Hardie NA, Conway JM, Leppik IE. Population pharmacokinetics of valproic acid concentrations in elderly nursing home residents. Ther Drug Monit  2007; 29:571-575.